Curiously, the A 1-42 level in the CSF is reduced and not correlated with motor dysfunction in PD patients compared to the controls (Buddhala et al
Confirm with your plan as always
It reads pathway-level variants in FTO, GLP1R, MC4R and TCF7L2 that describe your baseline GLP-1 and energy-balance biology upstream context that stays relevant no matter which program writes the prescription
Ranking of these genes shows 15 main genetic mechanisms driving efficacy: Genetic contributions identified included leptin, dopamine, glutamate, PI3K-AKT, and histamine mediated signaling as well as other mechanisms Modulating motivation and rewards-based feeding, appetite regulation (positive and negative), energy balance, and glucose homeostasis Drivers of strong responses to GLP-1A drugs were also associated with insulin secretion, lipid metabolism, type-II diabetes risk, cardiac function, fatty acid oxidation, adipocyte differentiation, and obesity The biomarkers were identified in 100% of the patients
This prevents accidental underdosing or double-dosing